Severity of alcohol dependence is associated with the fatty acid amide hydrolase Pro129Thr missense variant.
The endocannabinoid system plays an important role in reward and addiction. One of the two main endocannabinoid neurotransmitters, anandamide, is metabolized by fatty acid amide hydrolase, an enzyme with a functional genetic polymorphism (FAAH Pro129Thr, rs324420). The Thr129 allele has been linked to problem drug and alcohol use, but the association has not been widely replicated and may be stronger for clinical measures of severity rather than categorical diagnosis. In the present study, we sought to determine whether the Thr129 allele was associated with both alcohol dependence (AD) diagnosis and severity in a sample of 1434 European American and African American individuals, 952 of whom were diagnosed with lifetime AD. Participants were genotyped for FAAH rs324420, and ancestry was determined via a genome-wide panel of ancestry informative markers. Subjects participated in Structured Clinical Interviews for psychiatric disorders and 90-day Timeline Followback interviews to assess recent alcohol use. European American participants with current AD had a higher Thr129 allele frequency than non-dependent controls. In European Americans with lifetime AD, there were significantly different distributions of drinking days and binge drinking days between the two genotype groups, with Thr129 carriers reporting a median of 10 fewer abstinent days and 13 more binge drinking days than Pro129/Pro129 homozygotes. In African American participants, there were no significant differences between Thr129 allele frequency in cases and controls and no significant differences in measures of AD severity by genotype. These findings provide evidence that the Pro129Thr missense variant is associated with AD severity in European Americans.
Section on Human Psychopharmacology, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Matthew E
ME
Sloan
Section on Human Psychopharmacology, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Joshua L
JL
Gowin
Section on Human Psychopharmacology, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Jia
J
Yan
Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Melanie L
ML
Schwandt
Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Primavera A
PA
Spagnolo
Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Hui
H
Sun
Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, USA.
Colin A
CA
Hodgkinson
Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.|Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, USA.
David
D
Goldman
Section on Human Psychopharmacology, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Vijay A
VA
Ramchandani
D000328:Adult; D001741:Black or African American / Q000235:genetics; D000437:Alcoholism / Q000235:genetics*; D000581:Amidohydrolases / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D012720:Severity of Illness Index; D044465:White People / Q000235:genetics; D000099252:Fatty Acid Amide Hydrolases
D000581:Amidohydrolases; D000099252:Fatty Acid Amide Hydrolases
Alcohol use disorder; endocannabinoids; genetics; polymorphism; rs324420